News Conference News ACC 2025 FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints L.A. McKeown April 03, 2025
News Conference News ACC 2024 Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It Michael O'Riordan March 27, 2024
News Conference News ACC 2023 IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF L.A. McKeown March 14, 2023
News Conference News ACC 2023 Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2 Michael O'Riordan March 09, 2023
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Conference News ACC 2021 Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF Michael O'Riordan May 25, 2021
News Conference News ACC 2021 Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF Yael L. Maxwell May 16, 2021
News Conference News ACC 2020 ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up Shelley Wood March 30, 2020
News Conference News ACC 2020 Statins May Have Protective Effect on Chemotherapy-Induced Cardiotoxicity Yael L. Maxwell March 19, 2020
News Conference News ACC 2019 Amlodipine the Key Component in Dual BP Therapy in Sub-Saharan Africa: CREOLE Caitlin E. Cox March 25, 2019
News Conference News ACC 2013 Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months Jason Kahn March 11, 2013